We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in G1 Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 88 → 0 (-88)

100% less capital invested

Capital invested by funds: $45.5M → $0 (-$45.5M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 88

Holders
–
Holders Change
-88
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
88
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$7.03M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$5.68M
3
WP
Woodline Partners
California
-$3.11M
4
Renaissance Technologies
Renaissance Technologies
New York
-$2.84M
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$2.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
– -$314K -137,921 Closed
Bank of New York Mellon
27
Bank of New York Mellon
New York
– -$304K -133,230 Closed
Fidelity Investments
28
Fidelity Investments
Massachusetts
– -$296K -129,638 Closed
Man Group
29
Man Group
United Kingdom
– -$291K -127,723 Closed
FCA
30
FinTrust Capital Advisors
South Carolina
– -$230K -100,780 Closed
ECM
31
ExodusPoint Capital Management
New York
– -$222K -97,580 Closed
UBS Group
32
UBS Group
Switzerland
– -$200K -87,637 Closed
FSA
33
Franklin Street Advisors
North Carolina
– -$190K -83,400 Closed
BC
34
Birchview Capital
Vermont
– -$182K -80,000 Closed
Bank of America
35
Bank of America
North Carolina
– -$179K -78,361 Closed
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
– -$171K -74,826 Closed
VF
37
Virtu Financial
New York
– -$170K -74,354 Closed
N
38
Nuveen
North Carolina
– -$153K -66,928 Closed
Jane Street
39
Jane Street
New York
– -$148K -64,916 Closed
GCM
40
Graham Capital Management
Connecticut
– -$126K -55,218 Closed
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
– -$115K -50,632 Closed
SG Americas Securities
42
SG Americas Securities
New York
– -$107K -47,124 Closed
AGM
43
Alpine Global Management
New York
– -$107K -46,728 Closed
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
– -$101K -44,500 Closed
CFD
45
Creative Financial Designs
Indiana
– -$93K -40,805 Closed
BPA
46
Beacon Pointe Advisors
California
– -$90.5K -39,700 Closed
RJFSA
47
Raymond James Financial Services Advisors
Florida
– -$84.3K -36,987 Closed
Invesco
48
Invesco
Georgia
– -$81.4K -35,709 Closed
Envestnet Asset Management
49
Envestnet Asset Management
Illinois
– -$80.5K -35,299 Closed
CL
50
Choreo LLC
Illinois
– -$87K -35,234 Closed
1
2
3 4

GTHX Hedge Fund Activity: Q3 2024 in Review

0 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2024, worth a combined $0 — down 100% from $45.5M a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of GTHX and 0 opened new positions — a net loss of 88 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $7.03M sold.

  • 0 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2024, down from 88 in Q2 2024.
  • Funds reported $0 of G1 Therapeutics, Inc. Common Stock stock for Q3 2024, down 100% quarter-over-quarter.
  • 0 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2024 and 88 closed out, a net change of -88 holders.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2024 was BlackRock, an estimated $7.03M sold.

Based on aggregated 13F filings for Q3 2024.